RxSight (NASDAQ: RXST) adds Cohen to key board committees

Rhea-AI Filing Summary

RxSight, Inc. filed an amendment to update a prior report about the appointment of Raymond W. Cohen to its Board of Directors. The new filing explains that, on August 14, 2025, the board appointed Cohen to both the Compensation Committee and the Audit Committee, effective immediately.

After these changes, the Compensation Committee consists of Robert J. Palmisano (Chair), J. Andy Corley, Robert Warner, and Raymond W. Cohen. The Audit Committee consists of Julie B. Andrews (Chair), Juliet Tammenoms Bakker, Tamara R. Fountain, M.D., and Raymond W. Cohen.

true000111148500011114852025-07-312025-07-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K/A

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 31, 2025

RxSight, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-40690	94-3268801
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
100 Columbia
Aliso Viejo, California				92656
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (949) 521-7830

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		RXST		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

This Amendment No. 1 to Current Report on Form 8-K/A (the “Amendment”) amends the Current Report on Form 8-K of RxSight, Inc. (the “Company”) dated July 31, 2025 and filed with the Securities and Exchange Commission on August 4, 2025 (the “Original Form 8-K”), which disclosed the appointment of Raymond W. Cohen to the Board of Directors of the Company (the “Board”), effective July 31, 2025. At the time of filing the Original Form 8-K, no determination had been made with respect to the appointment of Mr. Cohen to any committees of the Board.

This Amendment is being filed solely to report that on August 14, 2025, the Board, including each member of the Corporate Governance and Nominating Committee of the Board, appointed Mr. Cohen to the Compensation Committee of the Board (the “Compensation Committee”) and the Audit Committee of the Board (the “Audit Committee”), effective immediately. Effective upon such appointment to the Compensation Committee, the members of the Compensation Committee are Robert J. Palmisano (Chair), J. Andy Corley, Robert Warner, and Raymond W. Cohen. Effective upon such appointment to the Audit Committee, the members of the Audit Committee are Julie B. Andrews (Chair), Juliet Tammenoms Bakker, Tamara R. Fountain, M.D, and Raymond W. Cohen.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			RxSight, Inc.
Date:	August 15, 2025	By:	/s/ Shelley Thunen
			Name: Shelley Thunen Title: Co-President and Chief Financial Officer

FAQ

What does RxSight (RXST) disclose in this 8-K/A filing?

RxSight updates a prior board appointment disclosure. The company reports that director Raymond W. Cohen was appointed to its Compensation Committee and Audit Committee on August 14, 2025, and lists the full membership of both committees after these changes.

Which board committees did RxSight add Raymond W. Cohen to?

Raymond W. Cohen was appointed to RxSight’s Compensation Committee and Audit Committee. These appointments were approved by the board, including the Corporate Governance and Nominating Committee members, and became effective immediately on August 14, 2025, expanding his responsibilities beyond general board service.

Who are the members of RxSight’s Compensation Committee after this change?

Following Cohen’s appointment, RxSight’s Compensation Committee includes Robert J. Palmisano (Chair), J. Andy Corley, Robert Warner, and Raymond W. Cohen. This committee oversees executive and director compensation matters as part of the company’s overall corporate governance structure described in the filing.

Who are the members of RxSight’s Audit Committee after this filing?

The Audit Committee now consists of Julie B. Andrews (Chair), Juliet Tammenoms Bakker, Tamara R. Fountain, M.D., and Raymond W. Cohen. This committee is responsible for overseeing financial reporting and audit matters, and Cohen’s addition broadens the group’s director representation.

Why did RxSight file an amendment instead of a new 8-K?

RxSight previously reported Cohen’s board appointment without committee assignments. At that time no committee decisions had been made. This Amendment No. 1 updates the earlier disclosure solely to reflect his subsequent appointments to the Compensation and Audit Committees on August 14, 2025.